白癜风
医学
皮肤病科
补骨脂素
不利影响
PUVA疗法
紫外线a
紫外线疗法
治疗方式
外科
内科学
银屑病
遗传学
生物
DNA
作者
Bakr Mohamed El-Zawahry,Maha Fathy Elmasry,Amira Ragab
摘要
Summary Introduction Acral vitiligo is a resistant subtype of vitiligo that does not respond easily to any treatment modality. Ultraviolet A1 (UVA1) (340‐400 nm) therapy can penetrate the deep dermis of the skin and is relatively free of adverse effects associated with different phototherapeutic modalities. This study's objective was to evaluate the effect of medium‐dose long‐wavelength UVA1 (40‐70 J) in acral vitiligo treatment and compare it with topical psoralen plus ultraviolet A (topical PUVA). Methods Patients in this randomized‐controlled comparative clinical trial were divided into two groups, medium‐dose UVA1 group and topical PUVA group (10 acral vitiligo patients each). Patients received 36 sessions of phototherapy over a period of 12 weeks. Every patient was clinically evaluated monthly as regards the appearance of new lesions or increase in diameter of the current lesion according to point counting and vitiligo area severity index. Results No statistically significant clinical difference was found between patients in UVA1 and topical PUVA groups regarding response and pattern of response ( P > 0.05). Conclusion Ultraviolet A1 seems to be of limited use as a monotherapy in acral vitiligo treatment. However, more studies combining it with other treatment modalities as systemic steroids and/or using higher UVA1 doses may prove beneficial.
科研通智能强力驱动
Strongly Powered by AbleSci AI